Travere Therapeutics, Inc. (TVTX) - Stock Analysis
Last updated: Jan 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability swing ⢠Very high margins ⢠Debt-heavy balance TVTX swung from deep FY2024 operating losses to positive EBITDA and net income by 2025-Q3, driven by sustained ~97â99% gross margins, sharply lower R&D/opex and improved cash flow, but remains highly leveraged with large accumulated deficits and elevated market multiples.
Price Behavior
Key Price Behavior Insights: ⢠Steep intramonth drop ⢠Broken support ⢠Potential oversold bounce Support Level: $34â$36 Resistance Level: $34â$36 Over the last month TVTX has shifted from mid/high-$30s stability into a steep sell-offâfalling from ~$39.52 on 2026-01-02 to $29.11 on 2026-01-13âbreaking prior $34â$36 support now likely acting as resistance, signaling dominant downside momentum with possible short-term oversold relief but no confirmed reversal.
Sentiment & News
Key News Insights: ⢠Sales strength ⢠FDA delay ⢠Legal probes Travere reported strong 2025 sales and cash but an FDA sNDA extension for FILSPARI, a 32.8% stock drop and securities probes have created significant regulatory and legal overhang.
AI Summary
Travere's transition to a revenueâgenerating, highâmargin commercial company fundamentally reframes the investment case from pure pipeline value to one where sustained FILSPARI netâsales growth and contained grossâtoânet (vs guidance) must materially offset the binary FDA sNDA timing (Apr 2026) and active securities investigations â monitor monthly FILSPARI net sales, GâtoâN trends, and cash/debt runway as the specific triggers that will reârate the stock or force dilution.
Description
Travere Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for rare diseases. Its marketed portfolio includes treatments for bile acid disorders and a drug for cystinuria, while its pipeline comprises a Phase III program for kidney diseases and an investigational enzyme-replacement candidate for classical homocystinuria. The company conducts partnered research with the NIH and patient organizations on rare genetic conditions, was renamed from Retrophin in 2020, and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 29 | Jan 5 | TVTX | Travere Therapeutics, Inc. | Travere Therapeutics presents strong short-term growth backed by record sales and patient starts for FILSPARI, imminent FDA approval for FSGS indication with January 2026 expected, positive Phase 3 DUPLEX study data, improving liquidity, and strong technical momentum with a recent 14% share rally. | Closed | -2.0% |